Posted on

Cancer Vaccine at Medisun Regenerative Medical Center and Health Summit

Medisun Regenerative Medical Center and Health Summit

Cancer Vaccine | White House Cancer Lunar Plan | Cancer Proton Beam Treatment

ShenZhen- Hong Kong-GuangZhou

The Medisun Medical Health Summit, co-sponsored by Medisun Regenerative Medical Group, New Life Group and Sunshine Medical Group, was held in Shenzhen, Hong Kong and Guangzhou from September 6 to 9, 2017. The theme of this summit is centered around the prevention and treatment of cancer. The authoritative release of cancer vaccine is the strongest focus of this summit.  

Medisun Medical Group has invited a number of authoritative scientists, medical experts, industry leaders, government agency representatives, business leaders and socialites from the United States, Europe, Japan, Hong Kong and Mainland China to collaborate on cancer prevention worldwide. Leading medical health consultations such as therapeutic technologies, industry regulatory development, and medical platform construction have been fully explored. Nearly 5,000 entrepreneur representatives, medical experts and doctors from the Chinese health industry participated in the listening and sharing.

Dozens of media interviews and reports at the summit

Madison Cancer Vaccine Launch Ceremony

Chairman Danny Wong said: “The advent of cancer vaccine is the strongest gospel of cancer prevention!”

According to the World Health Organization (WHO), approximately 14 million new cancer cases are diagnosed each year worldwide, and this number is expected to reach 21 million by 2030. As global treatment costs rise, cancer prevention measures are becoming more and more important, which has also made cancer prevention and treatment a high-profile international issue. Medisun’s comprehensive introduction of cancer vaccines is undoubtedly the strongest gospel for cancer prevention. The WT1 gene is a gene representing tumorigenesis in humans, and all human cancers are associated with this genetic mutation. The Nobel Institute of Ecological Medical Sciences has discovered a pathway to inhibit mutations in the WT1 gene, which can be vaccinated to produce memory T cells that inhibit WT1 gene mutations, which are immune to humans.

In addition, Medisun is also committed to the development and clinical use of a variety of other vaccines. Most of the vaccine technology comes from the United States, investing in rapid response to the pandemic virus and cancer control vaccine technology platform, with a market size of more than 2 billion US dollars. The vaccines invested by Medisun can be modularized in Asia and China to produce vaccines that are fully compliant with the United States. Including: Zika virus, Chikungunya fever, Zika/Chikununya heat combination, Ebola virus, human papillomavirus HPV treatment vaccine, head and neck cancer, cervical cancer, cervical lesions, simple Herpesvirus HSV, hepatitis C virus HCV, hepatitis B virus HBV,etc.

Mr. Danny Wong, Chairman of Medici Medical Group, was interviewed by the media about the release of cancer vaccine.

Chairman Danny Wong specifically said: “China’s rapid economic development over the past 20 years has been accompanied by a wave of globalization. China has integrated into the international community in various fields. At the same time, China has introduced high-standard medical technologies and services from Europe, the United States and Japan. It is our mission to make full use of Hong Kong’s advantages as a mature international metropolis and special geographical factors to provide the world’s most advanced medical care to the people of the motherland.

On-site participants actively asked questions from the cancer vaccine and new cancer treatment technologies to participate in the seminar.

Medisun participates in the White House Cancer Month Plan

Mr. Terry Lierman said: “The greatest progress and breakthrough of mankind is the birth of cancer vaccine!”

Mr. Terry Lierman, a core member of the White House Cancer Month Program, the NIH of the National Institutes of Health, and the founder of the FDA Board of Directors and director of the Meditech Group, said that cancer landing is an amazing cause. It is planned to complete the treatment of 20,000 cancer patients with 60 different technologies worldwide by 2020. This is a task that would have taken at least 10 years to achieve, and we will now achieve it in 5 years. The cancer “moon landing plan” advocated by former US President Barack Obama in 2016 is also the focus of this summit. The plan is led by former Vice President Joe Biden. The goal is to break the boundaries that hinder the cooperation of researchers and accelerate the research of cancer diagnosis and treatment in the future. 5 years to double the progress of anti-cancer research. The six major US cancer “moon landing programs” include cancer vaccines, high-sensitivity cancer early detection, immunotherapy and combination therapy, single-cell genomic analysis of cancer cells and tumor microenvironment cells, new treatments for childhood cancer, and enhanced data. shared. To this end, the United States and Canada, Hong Kong, Germany, Switzerland, Japan, South Korea and other countries, the first-class research units to establish cooperative relations, large-scale joint cancer research and treatment, toward precision Medisun. The Medisun Medical Group is a member of the Cancer Month Program and will also participate in this historic mission.

Mr. Terry Lierman talks about McGrady’s participation in the White House Cancer Month Plan

Medisun introduces Mayo proton beam therapy

Dr. Michael Haddock said: “The Mayo proton beam is a great advancement in the precise treatment of cancer!”

As the Asian Medical Service Center of the Mayo Clinic in the United States, Medisun invited Dr. Michael Haddock, Chairman of the Mayo Radiation Oncology Clinical Practice Committee and Vice Chairman of the American Society of Surgery Oncology (ACOSOG) Committee to talk about radiotherapy for cancer. Dr. Haddock talked about the current Proton Bean, the world’s leading cancer radiotherapy technology, Mayo currently has the most authoritative equipment, operations and medical team for global proton beam therapy. Mayo’s proton beam therapy program is the exclusive feature of pen beam scanning. It can accurately target tumors and prevent healthy tissues from being affected, thus achieving ideal cancer treatment, especially for treating children with cancer. For cancers with high mortality and lung cancer, proton beam therapy has obvious advantages compared with traditional radiotherapy.

At the Hong Kong Summit, Dr. Michael Haddock (left), the authoritative doctor of Mayo cancer proton beam therapy, answered questions from guests at the scene.

Dr. Michael Haddock (left) and Mr. Terry Lierman (right), the authoritative doctors of Mayo cancer proton beam therapy, at the Guangzhou Summit.

Japanese NKT immune cell therapy

Dr. Degang said: “Cancer vaccine and NKT immune cell therapy are the strongest partner in cancer prevention and treatment!”

Haruhiro Tokuoka, CEO of Riken Immunization and Reproductive Medisun, Japan, Dr. Degang Governing, talked about immunotherapy for cancer. Japan has always been a pioneer in cancer immunotherapy and has extensive clinical experience. Japan Riken and Medisun have worked closely together and established the Medisun Precision Medical Joint Venture, which applies NKT immunocytotherapy outside the traditional cancer treatment to clinical treatment of various types of cancer in the early, middle and late stages, and has clinically proven to greatly improve cancer patients. High quality of immunotherapy at the same time as quality of life with almost no side effects.

Dr. Kazuoka Kazuo of Japan at the Hong Kong Summit to explain the effectiveness of NKT immune cell therapy in clinical treatment of cancer.  

Dean He Jianxing (second from right) of Guangzhou Medical First Hospital visited the Guangzhou Summit and participated in Dr. Degang Zhiwei (third from left) on cell immunotherapy

Precision Medisun and anti-cancer cancer

Ms. Yanglan said: “As a mother, I chose to give my daughter a HPV cervical cancer vaccine; now the launch of the cancer vaccine is even more exciting!”

In today’s society, everyone is tired of work, and it is often the easiest to ignore their good habits, which leads to the emergence of various diseases . In fact, “health is the first wealth of life”, Emerson’s famous interpretation perfectly interpreted the importance of a healthy life to people. Ms. Yang Lan, a well-known Chinese media person, attended the summit as a guest and shared ideas about health and happiness with the guests. She said that the pain caused by cancer patients to the family cannot be expressed in words, and health is good for every family. Precious, we need to follow the development of science and technology to update our medical knowledge. Nowadays, precision Medisun has brought us new choices. While we are not blindly following, we should fully understand the physical condition of ourselves and our families, and choose the right medical health program for ourselves.

Ms. Yang Yu shared about cancer treatment.  

Ms. Wu Shuqing, the Honorary Director of the World Trade Center Association and the Standing Committee of the National Committee of the Chinese People’s Political Consultative Conference, was unable to visit the summit due to the temporary overseas meeting. She also sent a congratulatory message to the summit and congratulated Chairman Danny Wong of the Medisun Medical Group: “The summit has deepened Hong Kong with the Chinese mainland again, we are highly concerned about the medical and health industry. Therefore, I believe that Medisun Medical Group will continue its leading position in the field of medical and health care. Since the beginning, I have seen the entire team of Medisun under the leadership of Chairman Danny Wong. Unremitting efforts and dedication, I am convinced that today’s event is only the beginning, I hope that more results will be shared with the whole society.”

As a pioneer in the field of stem cells, cancer prevention and treatment in the world of regenerative , Medisun Medical Group has been committed to introducing the world’s leading cancer prevention and treatment technologies and providing the most advanced, professional and excellent medical and health services to the society. The release of the cancer vaccine is a revolutionary advancement in the field of cancer prevention. Ancient smallpox is terminally ill, and now a single shot of smallpox disappears; in the past, hepatitis B was terminally ill, and now a vaccine is immunized for life; yesterday, cancer is terminally ill, and today’s cancer vaccine keeps cancer away. Time is advancing and science is progressing. We must have a mentality of accepting progress. We believe that cancer prevention can provide shelter for the family and the health and well-being of  society.

Stay tuned: Hong Kong’s latest publication “CAPITAL” magazine in September, cover story “Mr. Danny Wong, Chairman of Medisun Medical Group” and cover story “New Revolution in Medical Industry”.

You can contact the Hong Kong Medisun Regenerative Medical Center to receive a magazine. Contact as below:

Phone: +(852) 2582 0188

Email: info@medisun.hk

WeChat: medisuninfo

Website: www.medisun.hk

****************************************

Medisun Medical Group

Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative  products, as well as top hospitals and treatment centers. Located on the 25th floor of Ao Teng Plaza, Kowloon Bay, Hong Kong, the Medisun Reproductive Centre has a 50,000-square-foot stem cell GMP production facility, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to be rigorous and professional. The development process provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. More than 3,000 biomedical tests provide the most predictable health protection for the health of our clients. Medisun has been fully supporting the development of the new life and health platform, and is committed to the deepening of the new products and technologies of regenerative Medisun through this platform, truly benefiting the health of the whole society.

For more details, please visit http://www.medisun.hk/

Posted on

Cryolife tech news

Asian’s Godfather of Cord Blood, Professor Takahashi Tsuneo Joined the “Cryolife Cord Blood Bank” and “Hong Kong Medisun”

In May 2017, CRYOLIFE Cord Blood Bank (Hong Kong Medisun Medical Group members) formally appointed the Godfather of Cord Blood in Asia, Japanese regenerative medicine expert Professor Takahashi Tsuneo as the Chief Scientist. Professor Takahashi will lead all the cord blood stem cell research projects. Professor Takahashi has eras of experience in the field of regenerative medicine. In the past few decades, Professor Takahashi has established the standards of the Cryo-Cord Blood in Asia and lead a new prospective in the application and development of the cord blood industry.

It is well believes that by the joining of Professor Takahashi will convey a new development stage in the field of cord blood stem cells in Hong Kong. It will bring new opportunities for the expansion of Medisun Medical Group and the Cryolife Cord Blood Bank.

Professor Takahashi Tsuneo is committed to the field of regenerative medicine for more than 40 years (mainly in the field of stem cells and cord blood bank). Currently he serves as Chief Executive Officer of Japan LIFEBANK and Chief Scientist of Hong Kong Cryolife Cord Blood Bank (Cryolife is a members of the Medisun Group). Prof. Takashi Tsuneo graduated from the Hokkaido University in Sapporo, Japan with a Ph.D. degree. He became the scientist in the Red Cross of Bethesda, Maryland. He later worked at the Research center for Arthritis, Diabetes and Kidney diseases of the National Institutes of Health in Bethesda, Maryland. Professor Takahashi Tsuneo returned to Japan, became the Red Cross Hokkaido Blood Center’s Research Director in Sapporo. Professor Takahashi is not only a founding member of the International Cord Blood Bank Alliance (NETCORD), but also Director of the Tokyo Cord Blood Bank Cell Treatment Center at the University of Tokyo, Japan, and Director of Cellular Research and Development for research center for cell therapy in New York. Professor Takahashi is a Visiting Professor at a number of well-known institutions, including: Department of Cellular Processing, Institute of Medical Sciences, University of Tokyo, Head of Hematology, Tokyo University Hospital, Head of Embryonic Stem Cell Research, Faculty of Forensic Medicine, Kyoto University, Kobe University Institute of Medicine and Pathology, and Department of Medicine, Peking University, China.

Application of Cord Blood

Cord blood is originated in the fetus, and collected at the umbilical cord ligation when separated from the residual placenta. Nearly a decade of research and discovered that umbilical cord blood contain the human hematopoietic and the hematopoietic stem cells of the immune system. It can be used for hematopoietic stem cell transplantation, for the treatment of more than 80 kinds of diseases. Thus, the cord blood has become an important source of hematopoietic stem cells, especially for no directly related family members. The hematopoietic stem cells is a very important human biological for treatment of diseases.

Worldwide, cord blood has been used to treat various types of Leukemia, Aplastic Anemia, Lymphoma, Multiple Myeloma, Neuroblastoma, Mucopolysaccharide disease, Thalassemia, Bone Marrow Dysplasia syndrome, Primary Immunodeficiency Disease, Chronic Granuloma and other 80 kinds of diseases.

Clinical application case

* The world’s first cord blood transplantation: In 1988, a 5-year-old French boy, suffering from Cooley’s Anemia has been treated with the cord blood transplantation and with completely recovered.
* The world’s first autologous cord blood transplantation: In 1997, a 14-month-old Brazilian girl, with autologous cord blood successfully cured Neuroblastoma.
* The world’s first double dosages of cord blood transplantation: In 2000, the Institute of Hematology of the Peking University used the world’s first double dose of cord blood transplantation for the treatment of Acute Lymphoblastic Leukemia with good result. Now, the patient weight of 95 kg, is having a healthy life.
* Asia’s first autologous cord blood transplantation: In 2009, Beijing Children’s Hospital, a pediatric patient using his own cord blood for the treatment of Neuroblastoma. This is the first case of autologous cord blood treatment for pediatric case. The baby is treated and being fine after the transplantation.
* China treated a youngest and light weight baby: In 2009, Shanghai Dao Pei Hospital has successfully treated a 2 months old baby only weight – 5 kg, by using the cord blood transplantation treatment for Primary Immunodeficiency Disease.
* In China, the first mother received the son’s cord blood transplantation as treatment: In 2009, Chongqing Xinqiao Hospital, a female patient suffering from an Acute Non-Lymphocytic Leukemia was treated by using her son’s umbilical cord blood, together with his husband’s bone marrow for transplantation. She was discharged from the Intensive Care Unit after one month from the transplantation. This is the first case of mother using her child’s cord blood for transplantation.

Treatment prospects

Cell therapy has been a biological way for the treatment of a number of diseases in the 21st century. At the end of May 2014, the worldwide of related clinical research on the cord blood cell therapy, registered with the United States National Institutes of Health (NIH) reached a total of 928.

CRYOLIFE Cord Blood Bank – Hong Kong’s first private cord blood bank

CRYOLIFE Cord Blood Bank is the only one in Hong Kong with the most international professional certification, and is highly recommended by gynecologist, physicians and parents. CRYOLIFE was established in 1996 to create the first private cord blood storage program in Asia. Prior to the establishment of the cord blood bank in Japan, Singapore, mainland China, Taiwan and Malaysia. Cryolife upgrades the standards in the development and research in the laboratory equipment. It is the leader in Hong Kong and Asian in the cord blood industry. CRYOLIFE has been recognized by the American Association of Blood Banks (AABB) since 2007 as one of the world’s first recognized AABB-approved cord blood banks, and range the first 50 in the Cord Blood Bank’s list. Continuous assessment were done in 2009, 2011, 2013 and 2015 and has successfully passed the review, and gain the AABB certification until the end of 2017. The company is the only one in Hong Kong which has obtained a 10 consecutive years’ certification in the private cord blood bank. (In February 2017) Hong Kong Medisun Medical Group acquired 51% stake in CRYOLIFE Cord Blood Bank as its controlling shareholder.)

MEDISUN MEDICAL GROUP

Headquartered in Hong Kong, Headquartered in Hong Kong, the company is committed to investing in R & D and commercialization of global regenerative medicine products, as well as professional medical investment groups in top hospitals and treatment centers.

Medisun invests extensively in regenerative medicine and stem cell patented technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, neurological diseases, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical and the US Mayo Clinic, Harvard University Stem Cell Research Institute, Johns Hopkins School of Life Science Center launched a long-term cooperation program, co-investment in regenerative medicine and stem cell therapy technology. Medisun collaborates with them as the business owned holdings and holds global intellectual property rights.

The Medisun Regenerative Medical Center is located in Kowloon, Hong Kong , with 50,000 square feet of stem cell GMP production base, cancer treatment center and anti-aging center, bringing together European, Japanese, American and individual Chinese experts for rigorous professional development process by providing immune cell therapy and a variety of stem cell treatments. Medisun is also the Asian Center, a representative of the Mayo Clinic Asia service agencies. It provides Mayo remote consultation, the second diagnosis and treatment, so that Chinese patients can not enjoy the authority of the medical services. Mayo Clinic provides more than three thousand biomedical tests for the most predictable health protection for our customers’ health.

Medisun Regenerative Medicine Center (Mayo Asia Medical Service Center | Cancer Treatment Center | Anti-Aging Center)

Medisun Medical Laboratory (Hong Kong)

Source : http://www.medisun.hk/

Posted on

Medisun and Tsinghua University starting collaboration

The founding of Enterprise Fund for the Tsinghua University and Medisun Cell Technological Research and Regenerative Medicine

In April 26, 2017 Medisun Medical Group and Tsinghua University held a signing ceremony, formally announced the establishment of the “Tsinghua Medisun Cell Technology Research Institute” and setting up the “Tsinghua Medisun Cell Technology and Regenerative Enterprise Investment Fund”. At the time of the 106th anniversary of Tsinghua University, the signing ceremony was presided by the prof. Dong Chen, Dean of the School of medicine, Tsinghua University, with the signing officials, the Chairman of Medisun Medical Group Mr. Danny Wong, The Executive Director of Medisun Medical Group Dr. Wen Feng, Vice President of Tsinghua University and the Chairman of Tsinghua University Education Foundation Yang Bin, Tsinghua University Education Foundation Secretary-General Li Jiaqiang, Medical School’s party secretary Hongbo and many other college leaders attended the signing ceremony.

The signing parties: Tsinghua University School of Medicine Dong Chen and Medisun Medical Group Chairman Danny Wong

The global leading platform of Regenerative Medicine on Cell Technology : The Enterprise Fund for the Cell Technological Research and Regenerative Medicine is based on the advance technology, professional staffing, skill proficiency, resources and management experience of the Medisun Medical Group. Further enhanced by the quality and scientific research platform offered by the Tsinghua University, for the collaboration with the School of Medicine and the Tsinghua Chang Gung Memorial Hospital and other affiliated institutions. To focus on cell technology and cell therapy in the area of education, training, scientific research, clinical transformation and industrial development. Through the combination of the above strong elements, to reinforce the professional leadership of the School of Medicine of Tsinghua University.

The two parties will actively cooperate with the integration of professionals and the high-quality resources, to build the institute as:
* The world’s leading cell technology platform to support the training of professionals
* The world’s leading cell technology platform for research, development and clinical transformation
* The world’s leading platform for international cooperation for development of cell technology
* China as the most influential authority on cell technology and related laws, regulations and operational standards

Cell Technology and Regenerative Medicine Enterprise Investment Fund

At the time of setting up the research institute, Tsinghua University and Medisun Medical Group, National Investment Funds Limited (The Directors of Medisun Medical Group) also co-sponsored the establishment of Tsinghua Medisun Cell Technology and Regenerative Enterprise Investment Fund. The movement will attract more financial ventures to participate and invest the technology for further research, development and clinical transformation. The increase of the social capital can increase the investment in scientific research, and reduce the burden on the government and university’s expenses. This is to ensure the scientific research is carried out normally, to achieve the scientific research objectives. Secondly, the investment from the enterprise can motivate the research staff for better efficiency of the scientific research and to enhance the productivity. Thereby to enhance the brand value and social benefits.

The Enterprise Investment Fund will be included in the Tsinghua University School of Medicine’s overall industrial strategy. According to the management standard of the School of medicine, it will be used for the research and development, and clinical transformation with the Tsinghua Chang Gung Memorial Hospital, to accomplish the combination of leap forward development strategy. At the same time, to set up a 10 years plan on the Enterprise Investment Fund. The profit from the operating outcome will donate to the Institute for teaching, research and related charity projects to promote the cell technology and regenerative medicine for an sustainable development.

Life Science – a main agenda on the 13th Five – year Plan

Life science is one of the most rapid developing area of the twentieth century and become one of the most striking discipline of natural life science. From the early stage of the development of the cell technology and cell therapy has already heading a medical revolution. In compare with the traditional drug therapy and surgery, the cell technology has develop a new means as the third choice of treatment. With advance improvement, it can has a broad market and potential for further expansion. The General Secretary Xi Jinping pointed out at the National Science and Technology Innovation Conference that stem cell research, early diagnosis of cancer markers, human genome sequencing and other basic scientific breakthroughs, all these can become an influential factors for China to face the world. Enterprises place an important force for integration of science, technology and economic growth. As the investment on research, development and transformation will become the main drive of the technological innovation. To adjust the existing industry and local research institutions, enrich enterprise R & D strength, support enterprises to build national technology and innovation center, cultivate the industry which could become the business pioneer. The collaboration between Medisun and Tsinghua University is a strong response to the National thirteen five years plan’s development direction, and to create a comprehensive platform for research and development.

The cooperation with the Medisun and Tsinghua University will lead the growth of cell technology and cell therapy in China. This will further promote the establishment of a comprehensive laws and regulation on cellular technology, industry standards, norms, system for cultivation and high-end and quality scientific research. Also training of medical personnel, support the international exchanges, enhance the ability of independent innovation by building a world class cell technology and cell therapy transformation platform. Then China will own the world high-end standard expertise and transformation cell technology enterprise. Read extra info at http://www.medisun.hk/.

Posted on

Frost & Sullivan’s Indonesia Domestic Warehouse Services Provider of the Year

PT. Kamadjaja Logistics was recently named Frost & Sullivan’s 2017 Indonesia Domestic Warehouse Services Provider of the Year at the annual Frost & Sullivan Indonesia Excellence Awards ceremony, held at the Mandarin Oriental Hotel, Jakarta on 28 November 2017.

“Recognizing the importance of innovation and meeting customer needs, PT. Kamadjaja Logistics has focused on developing and improving its warehousing infrastructure and technologies. The company’s cutting edge warehousing facilities such as its successful KLOG PARK establishments have enabled customers to derive maximum value from top-notch services, allowing the company to enjoy a better relationship with customers,” said Norazah Bachok, Research Analyst for Transportation & Logistics at Frost & Sullivan.

She continued, “PT. Kamadjaja Logistics also aims for more partnerships with various regional participants to boost opportunities. An extensive product portfolio, new business chain ventures, regional partnerships, and expansion strategies allow the company to enhance its brand recognition and value in the industry.”

“We are delighted to receive the 2017 Indonesia Domestic Warehouse Services Provider of the Year award from Frost & Sullivan. This recognition is a huge encouragement to the team as we strive to provide value to our customers by delivering innovative and excellent logistics services,” said Ivy Kamadjaja, Deputy CEO of PT. Kamadjaja Logistics.

The recipients of the annual Frost & Sullivan Indonesia Excellence Awards were identified based on in-depth research conducted by Frost & Sullivan’s analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends.

The short-listed companies were then evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.

About PT. Kamadjaja Logistics

PT. Kamadjaja Logistics is widely recognized as a pioneer in the logistics industry in Indonesia. Established five decades ago it is now the largest Indonesian company that provides integrated and modern logistics solutions. Equipped with 29 Distribution Centers spread over 16 major cities in Indonesia and covering over 355 destinations, PT. Kamadjaja Logistics has the largest nationwide logistics network in the country.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion

Contact:
Fuad Misbah
Corporate Communications – Indonesia
Email: fuad.misbah@frost.com
http://www.frost.com

Posted on

Existing-Home Sales Soar 5.6 Percent in November to Strongest Pace in Over a Decade

Existing-home sales surged for the third straight month in November and reached their strongest pace in almost 11 years, according to the National Association of Realtors?. All major regions except for the West saw a significant hike in sales activity last month.

Lawrence Yun is chief economist and senior vice president of research at the National Association of Realtors(r). Yun oversees and is responsible for a wide range of research activity for the association including NAR’s Existing Home Sales statistics, Affordability Index, and Home Buyers and Sellers Profile Report. He regularly provides commentary on real estate market trends for its 1 million Realtor(r) members. (PRNewsFoto/National Association of Realtors)

Total existing-home sales1, https://www.nar.realtor/existing-home-sales, which are completed transactions that include single-family homes, townhomes, condominiums and co-ops, jumped 5.6 percent2 to a seasonally adjusted annual rate of 5.81 million in November from an upwardly revised 5.50 million in October. After last month’s increase, sales are 3.8 percent higher than a year ago and are at their strongest pace since December 2006 (6.42 million).

Lawrence Yun, NAR chief economist, says home sales in most of the country expanded at a tremendous clip in November. “Faster economic growth in recent quarters, the booming stock market and continuous job gains are fueling substantial demand for buying a home as 2017 comes to an end,” he said. “As evidenced by a subdued level of first-time buyers and increased share of cash buyers, move-up buyers with considerable down payments and those with cash made up a bulk of the sales activity last month. The odds of closing on a home are much better at the upper end of the market, where inventory conditions continue to be markedly better.”

The median existing-home price3 for all housing types in November was $248,000, up 5.8 percent from November 2016 ($234,400). November’s price increase marks the 69th straight month of year-over-year gains.

Total housing inventory4 at the end of November dropped 7.2 percent to 1.67 million existing homes available for sale, and is now 9.7 percent lower than a year ago (1.85 million) and has fallen year-over-year for 30 consecutive months. Unsold inventory is at a 3.4-month supply at the current sales pace, which is down from 4.0 months a year ago.

“The anticipated rise in mortgage rates next year could further cut into affordability if these staggeringly low supply levels persist,” said Yun. “Price appreciation is too fast in a lot of markets right now. The increase in homebuilder optimism must translate to significantly more new construction in 2018 to help ease these acute inventory shortages.”

First-time buyers were 29 percent of sales in November, which is down from 32 percent both in October and a year ago. NAR’s 2017 Profile of Home Buyers and Sellers – released earlier this year5 – revealed that the annual share of first-time buyers was 34 percent.

Matching the highest share since May, all-cash sales were 22 percent of transactions in November, which is up from 20 percent in October and 21 percent a year ago. Individual investors, who account for many cash sales, purchased 14 percent of homes in November, up from 13 percent last month and unchanged from a year ago.

“The elevated presence of investors paying in cash continues to add a layer of frustration to the supply and affordability headwinds aspiring first-time buyers are experiencing,” said Yun. “The healthy labor market and higher wage gains are expected to further strengthen buyer demand from young adults next year. Their prospects for becoming homeowners will only improve if more lower-priced and smaller-sized homes come onto the market.”

Properties typically stayed on the market for 40 days in November, which is up from 34 days in October but down from 43 days a year ago. Forty-four percent of homes sold in November were on the market for less than a month.

Realtor.com?’s Market Hotness Index, measuring time on the market data and listings views per property, revealed that the hottest metro areas in November were San Jose-Sunnyvale-Santa Clara, Calif.; Vallejo-Fairfield, Calif.; San Francisco-Oakland-Hayward, Calif.; San Diego-Carlsbad, Calif.; and Stockton-Lodi, Calif.

According to Freddie Mac, the average commitment rate for a 30-year, conventional, fixed-rate mortgage increased for the second straight month to 3.92 percent in November from 3.90 percent in October. The average commitment rate for all of 2016 was 3.65 percent.

On the topic of tax reform, NAR President Elizabeth Mendenhall, a sixth-generation Realtor? from Columbia, Missouri and CEO of RE/MAX Boone Realty, says it’s good news homeowners can continue to count on tax incentives such as the mortgage interest deduction and the state and local tax deduction.

“Only 6 percent of homeowners have mortgages exceeding $750,000, and only 5 percent pay more than $10,000 in property taxes, but most homeowners won’t itemize under the new regime,” she said. “While we’re pleased that important homeownership incentives such as the capital gains exclusion survived in conference, additional changes are required to truly incentivize homeownership in the tax code.”

Distressed sales6 – foreclosures and short sales – were 4 percent of sales for the fourth straight month in November, and are down from 6 percent a year ago. Three percent of November sales were foreclosures and 1 percent were short sales.

Single-family and Condo/Co-op Sales
Single-family home sales grew 4.5 percent to a seasonally adjusted annual rate of 5.09 million in November from 4.87 million in October, and are now 3.2 percent above the 4.93 million pace a year ago. The median existing single-family home price was $248,800 in November, up 5.4 percent from November 2016.

Existing condominium and co-op sales increased 14.3 percent to a seasonally adjusted annual rate of 720,000 units in November, and are now 7.5 percent above a year ago. The median existing condo price was $242,500 in November, which is 8.8 percent above a year ago.

Regional Breakdown
November existing-home sales in the Northeast leaped 6.7 percent to an annual rate of 800,000, (unchanged from a year ago). The median price in the Northeast was $273,600, which is 4.0 percent above November 2016.

In the Midwest, existing-home sales jumped 8.4 percent to an annual rate of 1.42 million in November, and are now 6.8 percent above a year ago. The median price in the Midwest was $196,100, up 8.8 percent from a year ago.

Existing-home sales in the South expanded 8.3 percent to an annual rate of 2.34 million in November, and are now 4.0 percent higher than a year ago. The median price in the South was $216,200, up 4.8 percent from a year ago.

Existing-home sales in the West declined 2.3 percent to an annual rate of 1.25 million in November, but are still 2.5 percent above a year ago. The median price in the West was $375,100, up 8.2 percent from November 2016.

The National Association of Realtors?, “The Voice for Real Estate,” is America’s largest trade association, representing 1.3 million members involved in all aspects of the residential and commercial real estate industries.

NOTE: For local information, please contact the local association of Realtors? for data from local multiple listing services. Local MLS data is the most accurate source of sales and price information in specific areas, although there may be differences in reporting methodology.

1 Existing-home sales, which include single-family, townhomes, condominiums and co-ops, are based on transaction closings from Multiple Listing Services. Changes in sales trends outside of MLSs are not captured in the monthly series. NAR rebenchmarks home sales periodically using other sources to assess overall home sales trends, including sales not reported by MLSs.

Existing-home sales, based on closings, differ from the U.S. Census Bureau’s series on new single-family home sales, which are based on contracts or the acceptance of a deposit. Because of these differences, it is not uncommon for each series to move in different directions in the same month. In addition, existing-home sales, which account for more than 90 percent of total home sales, are based on a much larger data sample – about 40 percent of multiple listing service data each month – and typically are not subject to large prior-month revisions.

The annual rate for a particular month represents what the total number of actual sales for a year would be if the relative pace for that month were maintained for 12 consecutive months. Seasonally adjusted annual rates are used in reporting monthly data to factor out seasonal variations in resale activity. For example, home sales volume is normally higher in the summer than in the winter, primarily because of differences in the weather and family buying patterns. However, seasonal factors cannot compensate for abnormal weather patterns.

Single-family data collection began monthly in 1968, while condo data collection began quarterly in 1981; the series were combined in 1999 when monthly collection of condo data began. Prior to this period, single-family homes accounted for more than nine out of 10 purchases. Historic comparisons for total home sales prior to 1999 are based on monthly single-family sales, combined with the corresponding quarterly sales rate for condos.

2 November’s monthly increase of 5.6 percent is the largest monthly gain since December 2015 (12.1 percent), which was influenced by delayed closings resulting from the rollout of the Know Before You Owe initiative in late 2015.

3 The median price is where half sold for more and half sold for less; medians are more typical of market conditions than average prices, which are skewed higher by a relatively small share of upper-end transactions. The only valid comparisons for median prices are with the same period a year earlier due to seasonality in buying patterns. Month-to-month comparisons do not compensate for seasonal changes, especially for the timing of family buying patterns. Changes in the composition of sales can distort median price data. Year-ago median and mean prices sometimes are revised in an automated process if additional data is received.

The national median condo/co-op price often is higher than the median single-family home price because condos are concentrated in higher-cost housing markets. However, in a given area, single-family homes typically sell for more than condos as seen in NAR’s quarterly metro area price reports.

4 Total inventory and month’s supply data are available back through 1999, while single-family inventory and month’s supply are available back to 1982 (prior to 1999, single-family sales accounted for more than 90 percent of transactions and condos were measured only on a quarterly basis).

5 Survey results represent owner-occupants and differ from separately reported monthly findings from NAR’s Realtors?Confidence Index, which include all types of buyers. Investors are under-represented in the annual study because survey questionnaires are mailed to the addresses of the property purchased and generally are not returned by absentee owners. Results include both new and existing homes.

6 Distressed sales (foreclosures and short sales), days on market, first-time buyers, all-cash transactions and investors are from a monthly survey for the NAR’s Realtors? Confidence Index, posted at nar.realtor.

NOTE: NAR’s Pending Home Sales Index for November is scheduled for release on December 27, and Existing-Home Sales for December will be released January 24; release times are 10:00 a.m. ET.

From https://www.prnewswire.com/news-releases/existing-home-sales-soar-56-percent-in-november-to-strongest-pace-in-over-a-decade-300573924.html

Posted on

New Horizons for Clean Power Generation in Japan

The post-Fukushima shutdown of Japan’s nuclear reactors and subsequent demand for energy self-sufficiency due to costly fuel imports, coupled with the Japanese government’s ambitious emissions reduction targets for 2020, have stimulated growth in new renewable energy sources in the country.

Currently, renewable power accounts for approximately 15% of total electricity generation in Japan, while hydro and solar power occupy a combined 12% share, aided by attractive government subsidies for these technologies.

Although the government has been proactive in recent initiatives to identify and promote potential areas for exploration and development of geothermal power, there has not been any significant development of the technology in the country in the last decade.

In fact, a new whitepaper by Frost & Sullivan underlines that geothermal power contributes a meagre 0.3% to total electricity generation, despite the country possessing the third largest geothermal resource in the world, representing a power generation potential of 23 GW.

While development of the technology at medium and high temperatures is characterised by stagnation, increased investment and technological innovation targeting low-temperature geothermal power (<120?C), historically used primarily for heating purposes, are expected to significantly increase the addressable market potential for geothermal power.

Commenting on this new growth market, Ross Bruton, Programme Manager & Principal for Smart Energy Systems at Frost & Sullivan, emphasised that harnessing the potential offered by low-temperature geothermal power will help achieve Japan's power security and emission reduction goals.

The advent of technological innovations is significantly increasing system performance and cost efficiencies at low temperatures, set to boost uptake levels. Mr Bruton commented: "Additional drivers include multi-application benefits for hot spring (onsen) owners, attractive feed-in-tariffs and grant financing offered by government, relaxation of development restrictions in national parks, and a lack of environmental assessment requirements for small scale geothermal power."

"These drivers, combined with improved cooperation at the community level, is expected to set up low-temperature geothermal power as a potential game-changer in the exploitation of the country's geothermal potential, and marks a contributory step towards the establishment of a stable, low-emission power industry in Japan," he added.

Japan's domestic energy crisis is opening up interesting opportunities for foreign companies to contribute to the national geothermal portfolio. However, companies will need to compete against well-established alternative technologies, such as solar photovoltaic, to gain a foothold in the market.

Utham Ganesh, Research Analyst at Frost & Sullivan, points out that "building strong local and community relations represents a key success criterion for project development, due to the strong cultural values attached to hot springs in the country and the resistance shown for fear of environmental impact."

For further insights into the potential of low-temperature geothermal energy in Japan, read the full whitepaper "Japan Onsen Power – New Horizons for Clean Power Generation from Low-Temperature Geothermal Energy" online and download your complimentary copy here.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

For further information, please contact:

Kristina Menzefricke
Corporate Communications – Frost & Sullivan, Europe
P: +44 (0)208 996 8589
E: kristina.menzefricke@frost.com
http://www.frost.com

SOURCE Frost & Sullivan
Related Links
http://www.frost.com